Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

142
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

474
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
474
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence-Driven Discovery of Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as Novel Phosphodiesterase 4 Inhibitors for Treating Idiopathic Pulmonary Fibrosis.

Journal of medicinal chemistry·2025
Same author

Discovery and optimization of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel phosphodiesterase 4 inhibitors.

Molecular diversity·2024
Same author

Regulation of the physiology and virulence of Ralstonia solanacearum by the second messenger 2',3'-cyclic guanosine monophosphate.

Nature communications·2023
Same author

Identification of Novel Quinolin-2(1<i>H</i>)-ones as Phosphodiesterase 1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

Journal of medicinal chemistry·2023
Same author

Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.

Journal of medicinal chemistry·2022
Same author

Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells.

RSC advances·2022

Related Experiment Video

Updated: May 23, 2025

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

2.3K

Structure-Based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Antipsoriasis Effects.

Furong Zhang1,2, Tiansheng Zheng1, Xue Wang1

  • 1Key Laboratory of Tropical Biological Resources of Ministry of Education and Hainan Engineering Research Center for Drug Screening and Evaluation, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.

Journal of Medicinal Chemistry
|March 11, 2025
PubMed
Summary

Researchers developed a new drug, L30, that potently inhibits PDE4. This novel compound shows promise as a potential treatment for psoriasis by reducing inflammation.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K

Related Experiment Videos

Last Updated: May 23, 2025

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

2.3K
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.5K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.5K

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Dermatology

Background:

  • Psoriasis is a chronic inflammatory skin condition significantly impacting patient quality of life.
  • Current psoriasis treatments manage symptoms but do not offer a cure, highlighting an unmet medical need.

Purpose of the Study:

  • To develop a novel phosphodiesterase 4 (PDE4) inhibitor with improved potency and selectivity for psoriasis treatment.
  • To evaluate the therapeutic potential of the novel inhibitor, L30, in preclinical models of psoriasis.

Main Methods:

  • Structure-based optimization of the natural product moracin M led to the discovery of L30.
  • In vitro assays assessed L30's potency and selectivity against PDE4 and other phosphodiesterase families.
  • Cell-based assays evaluated L30's ability to inhibit inflammatory cytokine and chemokine release.
  • An imiquimod-induced mouse model was used to assess L30's efficacy following topical administration.

Main Results:

  • L30 demonstrated significantly enhanced potency (IC50 of 8.6 nM) and selectivity (>201-fold) compared to moracin M.
  • Co-crystal structure analysis revealed a distinct binding pattern of L30 with PDE4 compared to roflumilast.
  • L30 effectively suppressed inflammatory mediator release in Raw264.7 and HaCaT cell lines.
  • Topical application of L30 showed significant therapeutic effects in a psoriasis mouse model.

Conclusions:

  • The novel PDE4 inhibitor L30 exhibits potent anti-inflammatory activity and efficacy in a preclinical psoriasis model.
  • L30 represents a promising novel lead compound for the development of new psoriasis therapies.